New Multiple Myeloma Treatment Receives Accelerated Approval from FDA
The FDA has granted accelerated approval to Lynozyfic (linvoseltamab-gcpt), a groundbreaking bispecific antibody treatment for patients with relapsed or refractory multiple myeloma. Developed by Regeneron Pharmaceuticals, this innovative therapy works as a B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, offering new hope for patients who have exhausted other treatment options.
The approval, announced on July 2, 2025, represents a significant advancement in cancer immunotherapy, particularly for multiple myeloma patients who have limited treatment alternatives. This bispecific antibody essentially acts as a bridge, connecting cancer cells to immune cells to enhance the body’s natural ability to fight the disease.
Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. While treatments have improved over the years, many patients eventually become resistant to existing therapies. Lynozyfic’s unique mechanism of action could provide a crucial new weapon in the fight against this challenging cancer.
Source: https://www.drugs.com/newdrugs.html